The annual report, which draws on QBE’s proprietary claims data, found that neoplasms account for 36% of all stop-loss claim reimbursements, maintaining their position as the leading diagnosis across all deductible levels. At the $200,000 deductible level, neoplasm claim severity rose 12% from the average of prior years, while frequency climbed nearly 30%. Across all conditions, the frequency of members exceeding $200,000 in annual claims per 10,000 employees increased by nearly 20% year on year, driven primarily by neoplasms, birth-related claims and circulatory diseases. Birth-related claim frequency more than doubled between 2024 and 2025.
Cancer claims and specialty drugs drive stop-loss cost surge: QBE
